1 SIMSTATIN TABLETS
SimStatin 5mg tablets
SimStatin 10mg tablets
SimStatin 20mg tablets
SimStatin 40mg tablets
SimStatin 80mg tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 5mg tablet contains simvastatin 5mg
Each 10mg tablet contains simvastatin 10mg
Each 20mg tablet contains simvastatin 20mg
Each 40mg tablet contains simvastatin 40mg
Each 80mg tablet contains simvastatin 80mg

Excipients with known effect
Butylated hydroxyanisole

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
SimStatin 5mg tablets are a yellow, oblong, biconvex, filmcoated tablet, scored and debossed with “5” on one side and debossed “SVT” on the other.

SimStatin 10mg tablets are a white oblong, biconvex, filmcoated tablet, scored and debossed with “10” on one side and debossed “SVT” on the other.

SimStatin 20mg tablets are a white oblong, biconvex, filmcoated tablet, scored and debossed with “20” on one side and debossed “SVT” on the other.

SimStatin 40mg tablets are a white oblong, biconvex, filmcoated tablet, scored and debossed with “40” on one side and debossed “SVT” on the other.

SimStatin 80mg tablets are a white oblong, biconvex, filmcoated tablet, debossed with “80” and “SVT” on the other.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Patients at High Risk of Coronary Heart Disease (CHD) or With Existing CHD

In patients at high risk of CHD (with or without hyperlipidemia but with a total cholesterol of >3.5 mmol/L), ie., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD, SimStatin is indicated to:
• Reduce the risk of total mortality by reducing CHD deaths;
• Reduce the risk of major vascular events (a composite of non-fatal myocardial infarction, CHD death, stroke, or revascularization procedures);
• Reduce the risk of major coronary events (a composite of non-fatal myocardial infarction or CHD deaths);
• Reduce the risk of stroke;
• Reduce the need for coronary revascularization procedures (including coronary artery bypass grafting and percutaneous transluminal coronary angioplasty);
• Reduce the need for peripheral and other non-coronary revascularization procedures;
• Reduce the risk of hospitalisation for angina pectoris.

In patients with diabetes, SimStatin reduces the risk of developing peripheral macrovascular complications (a composite of peripheral revascularization procedures, lower limb amputations, or leg ulcers).

In hypercholesterolemic patients with coronary heart disease, SimStatin slows the progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions.

Patients with Hyperlipidemia

• SimStatin is indicated as an adjunct to diet to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), triglycerides TG, and, apolipoprotein B (apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia including heterozygous familial hypercholesterolemia (Fredrickson type IIa), or combined (mixed) hyperlipidemia (Fredrickson type IIb) when response to diet and other non-pharmacological measures is inadequate. SimStatin therefore lowers the LDL-C/HDL-C and total-C/HDL-C ratios.
• SimStatin is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia) with a baseline LDL cholesterol of < 3.37mmol/L and baseline triglyceride of > 2.26 mmol/L, despite adequate dietary intervention.
• SimStatin is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia) not responding to diet alone with VLDL/TG ratios > 0.25, and raised total cholesterol, TG and Apo-E levels.
• SimStatin is also indicated as an adjunct to diet and other non-dietary measures for the treatment of patients with homozygous familial hypercholesterolemia to reduce elevated total-C, LDL-C and apoB.

Paediatric Patients with Heterozygous Familial Hypercholesterolemia

SimStatin is indicated as an adjunct to diet to reduce total-C, LDL-C, TG, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolemia (HeFH).
4.2 Dose and method of administration

The dosage range for SimStatin is 5-80mg/day, given as a single dose in the evening. Adjustments of dosage, if required, should be made at intervals of not less than 4 weeks, to a maximum of 80mg/day given as a single dose in the evening.

The 80mg dose of SimStatin is only recommended in patients with a high risk for cardiovascular complications who have not achieved their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks (see section 4.4).

SimStatin may be taken with or without food.

Patients at High Risk of Coronary Heart Disease (CHD) or with Existing CHD

The usual starting dose of SimStatin is 40mg/day given as a single dose in the evening in patients at high risk of CHD (with or without hyperlipidemia) i.e., patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing CHD. Medicine therapy can be initiated simultaneously with diet and exercise.

Patients with Hyperlipidemia who are not in the risk categories above

The patient should be placed on a standard cholesterol-lowering diet before receiving SimStatin and should continue on this diet during treatment with SimStatin. The usual starting dose is 20 mg/day given as a single dose in the evening. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40mg/day given as a single dose in the evening. Patients who require only a moderate reduction of LDL-C may be started at 10mg. Adjustments of dosage including starting dose, if required, should be made as specified above.

Patients with Homozygous Familial Hypercholesterolemia

Based on results of a controlled clinical study, the recommended dosage for patients with homozygous familial hypercholesterolemia is SimStatin 40 mg/day in the evening or 80 mg/day in 3 divided doses of 20 mg, 20 mg, and an evening dose of 40 mg. The 80 mg dose is only recommended when the benefits are expected to outweigh the potential risks (see sections 4.3 and 4.4). SimStatin should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.
Concomitant Therapy

SimStatin is effective alone or in combination with bile acid sequestrants.

In patients taking amiodarone, diltiazem or verapamil or lipid-lowering doses (≥ 1 g/day) of niacin concomitantly with SimStatin, the dose of SimStatin should not exceed 20 mg/day (see sections 4.4 and 4.5).

In patients taking amlodipine concomitantly with SimStatin, the dose of SimStatin should not exceed 40 mg/day (see sections 4.4 and 4.5).

Dosage in Renal Insufficiency
Because SimStatin does not undergo significant renal excretion, modification of dosage should not be necessary in patients with moderate renal insufficiency.

In patients with severe renal insufficiency (creatinine clearance < 30 ml/min), dosages above 10 mg/day should be carefully considered and, if deemed necessary, implemented cautiously.

Dosage in Paediatric Patients (10-17 years of age) with Heterozygous Familial Hypercholesterolemia

The recommended usual starting dose is 10 mg once a day in the evening. The recommended dosing range is 10-40 mg/day; the maximum recommended dose is 40 mg/day. Doses should be individualized according to the recommended goal of therapy (see section 5.1).

4.3 Contraindications

- Hypersensitivity to any component of this preparation.
- Active liver disease or unexplained persistent elevations of serum transaminases.
- Pregnancy and nursing (see also section 4.6).
- Myopathy secondary to other lipid lowering agents.
- Concomitant administration of potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, posaconazole, HIV protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone) (see sections 4.4 and 4.5).
- Concomitant administration of gemfibrozil, cyclosporine, or danazol (see section 4.4).

4.4 Special warnings and precautions for use

Type 2 Diabetes Mellitus
There is sufficient evidence to support an association between statin use and new onset type 2 diabetes mellitus; however, the risk appears to be mainly in patients already at increased risk of developing diabetes. Risk factors for the development of diabetes include raised fasting blood glucose, history of hypertension, raised triglycerides and raised body mass. Patients at risk should be monitored both clinically and biochemically according to national guidelines.
There is insufficient evidence to confirm or exclude an increased risk for any individual statin or a dose-response relationship. The cardiovascular benefits of statin therapy continue to outweigh the risk of diabetes.

**Myopathy/Rhabdomyolysis**

Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above 10X the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Predisposing factors for myopathy include advanced age (≥65 years), female gender, uncontrolled hypothyroidism, and renal impairment.

The risk of myopathy/rhabdomyolysis is related to the dose of simvastatin. In a clinical trial database, it suggested that the incidence of myopathy was approximately 0.03%, 0.08% and 0.61% at 20, 40 and 80 mg/day, respectively with an average follow-up of at least 4 years. Clinical trial data also suggested that the incidence of myopathy cases (approximately half of all the myopathy cases observed) are the highest during the first year of treatment.

The risk of myopathy is greater in patients on simvastatin 80 mg compared with other statin-based therapies with similar LDL-C lowering efficacy. Therefore the 80 mg dose of simvastatin should only be used in patients at high risk for cardiovascular complications who have not achieve their treatment goals on lower doses and when the benefits are expected to outweigh the potential risks. In patients taking Simvastatin 80 mg for whom an interacting agent is needed, a lower dose of Simvastatin or an alternative statin-ezetimibe regimen with less potential for drug-drug interactions should be used (see sections 4.2 and 4.3).

All patients starting therapy with simvastatin, or whose dose of simvastatin is being increased, should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness. Simvastatin therapy should be discontinued immediately if myopathy is diagnosed or suspected. The presence of these symptoms, and a CK level >10 times the upper limit of normal indicates myopathy. In most cases, when patients were promptly discontinued from treatment, muscle symptoms and CK increases resolved. Periodic CK determinations may be considered in patients starting therapy with simvastatin or whose dose is being increased. Periodic CK determinations are recommended for patients titrating to the 80 mg dose. There is no assurance that such monitoring will prevent myopathy.

Many of the patients who have developed rhabdomyolysis on therapy with simvastatin have had complicated medical histories, including renal insufficiency usually as a consequence of long-standing diabetes mellitus. Such patients merit closer monitoring. Therapy with simvastatin should be temporarily stopped a few days prior to elective major surgery and when any major medical or surgical condition supervenes.
Drug Interactions
The risk of myopathy/rhabdomyolysis is increased by concomitant use of simvastatin with the following medicines:

Contraindicated medicines
Potent inhibitors of CYP3A4 eg., itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, or nefazodone, particularly with higher doses of simvastatin (see section 4.5) are contraindicated. If treatment with itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment (see sections 4.3, 4.5 and 5.2).

Concomitant use of gemfibrazil, cyclosporine or danazol is contraindicated (see sections 4.3, 4.5 and 5.2)

Other medicines
- Amiodarone with higher doses of simvastatin (see section 4.5). In an ongoing clinical trial, myopathy has been reported in 6% of patients receiving simvastatin 80 mg and amiodarone. The dose of SimSatin should not exceed 20mg per day in patients receiving concomitant treatment with amiodarone (see sections 4.2 and 4.5).

- Diltiazem or verapamil: The dose of SimStatin should not exceed 20 mg daily in patients receiving concomitant treatment with verapamil or diltiazem (see sections 4.2 and 4.5). In a pharmacokinetic study, co-administration of diltiazem and simvastatin resulted in a mean 70% increase in systemic exposure to total simvastatin-derived HMG-CoA reductase inhibitory activity. Patients on diltiazem treated concomitantly with simvastatin 80 mg have a slightly increased risk of myopathy. The risk of myopathy is approximately 1% in these patients.

- Amlodipine: In a clinical trial, patients on amlodipine treated concomitantly with simvastatin 80 mg had a slightly increased risk of myopathy. The dose of SimSatin should not exceed 40 mg daily in patients receiving concomitant medication with amlodipine (see sections 4.2 and 4.5).

- Moderate inhibitors of CYP3A4: Patients taking other medicines labelled as having a moderate inhibitor effect on CYP3A4 concomitantly with SimStatin, particularly higher SimStatin doses, may have an increased risk of myopathy.

- Other Fibrates: The safety and effectiveness of SimStatin administered with fibrates have not been studies. Therefore, the concomitant use of SimStatin and fibrates should be avoided. Concomitant use of gemfibrozil is contraindicated (see sections 4.3 and 4.5).

- Fusidic acid: Patients on fusidic acid treated concomitantly with simvastatin may have an increased risk of myopathy Patients on fusidic acid and SimStatin should be closely monitored. Temporary suspension of SimStatin treatment may be considered (see sections 4.5 and 5.2).
• Niacin (≥1 g/day): The dose of SimStatin should not exceed 20 mg daily in patients receiving concomitant medication with niacin (nicotinic acid) ≥1 g/day. Cases of myopathy/rhabdomyolysis have been observed with simvastatin coadministered with lipid modifying doses (≥1 g/day) of niacin. An interim analysis of a double-blind randomised global multicentre clinical trial suggested that the incidence of myopathy among Chinese is higher than in non-Chinese patients. Therefore, caution should be used when treating Chinese patients with SimStatin (particularly doses of 40 mg or higher) co-administered with lipid modifying doses (≥1 g/day) of niacin or niacin-containing products. Because the risk of myopathy is dose-related, the use of SimStatin 80 mg with lipid modifying doses (≥1 g/day) of niacin or niacin-containing products is not recommended in Chinese patients. It is unknown whether there is an increased risk of myopathy with co-administration in other Asian patients (see section 4.5).

Hepatic Effects
It is recommended that liver function tests (LFT) be performed before treatment begins and thereafter when clinically indicated. Patients titrated to the 80mg dose should receive an additional test prior to titration, 3 months after titration to the 80mg dose, and periodically thereafter (e.g., semi-annually) for the first year of treatment. Special attention should be paid to patients who develop elevated serum transaminase levels, and in these patients, measurements should be repeated promptly and then performed more frequently. If the transaminase levels show evidence of progression, particularly if they rise to 3X ULN and are persistent, the medicine should be discontinued. Note that ALT may emanate from muscle, therefore ALT rising with CK may indicate myopathy (see section 4.4).

In clinical studies persistent increases (to more than 3X ULN) in serum transaminases have occurred in a few adult patients who received simvastatin. When the medicine was interrupted or discontinued in these patients, the transaminase levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms. There was no evidence of hypersensitivity. Some of these patients had abnormal LFT prior to therapy with simvastatin and/or consumed substantial quantities of alcohol.

In the 4S, the number of patients with more than one transaminase elevation to >3X ULN, over the course of the study, was not significantly different between the simvastatin and placebo groups (14 [0.7%] vs. 12 [0.6%]). The frequency of single elevations of SGPT (ALT) to 3X ULN was significantly higher in the simvastatin group in the first year of the study (20 vs. 8, p=0.023), but not thereafter. Elevated transaminases resulted in the discontinuation of 8 patients from therapy in the simvastatin group (n=2,221) and 5 in the placebo group (n=2,223). Of the 1986 simvastatin treated patients in 4S with normal liver function tests (LFTs) at baseline, only 8 (0.4%) developed consecutive LFT elevations to > 3X ULN and/or were discontinued due to transaminase elevations during the 5.4 years (median follow-up) of the study. All of the patients in this study received a starting dose of 20mg of simvastatin; 37% were titrated to 40mg.

In 2 controlled clinical studies in 1105 patients, the 6 month incidence of persistent hepatic transaminase elevations considered medicine-related was 0.7% and 1.8% at the 40 and 80 mg dose respectively.
In the Heart Protection Study, in which 20,536 patients were randomised to receive simvastatin 40mg/day or placebo, the incidences of elevated transaminases (> 3X ULN confirmed by repeat test) were 0.21% (n = 21) for patients treated with simvastatin and 0.09% (n = 9) for patients treated with placebo.

The medicine should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver diseases or unexplained transaminase elevations are contraindications to the use of simvastatin.

As with other lipid-lowering agents, moderate (less than 3X ULN) elevations of serum transaminases have been reported following therapy with simvastatin. These changes appeared soon after initiation of therapy with simvastatin, were often transient, were not accompanied by any symptoms and interruption of treatment was not required.

**Interstitial Lung Disease**

Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy. Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease. Statin therapy should be discontinued.

**Paediatric Use**

Safety and effectiveness of simvastatin in patients 10-17 years of age with heterozygous familial hypercholesterolemia have been evaluated in a controlled clinical trial in adolescent boys and in girls who were at least one year post-menarche. Patients treated with simvastatin had an adverse experience profile generally similar to that of patients treated with placebo. Doses greater than 40 mg have not been studied in this population. In this limited controlled study, there was no detectable effect on growth or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls (see sections 4.2, 4.8 and 5.1) Adolescent females should be counselled on appropriate contraceptive methods while on simvastatin therapy (see sections 4.3, 4.4 and 4.6). Simvastatin has not been studied in patients younger than 10 years of age, nor in pre-menarchal girls.

**Elderly**

For patients over the age of 65 years who received simvastatin in controlled clinical studies, efficacy, as assessed by reduction in total and LDL-C levels, appears similar to that seen in the population as a whole, and there is no apparent increase in the frequency of clinical or laboratory adverse findings.

**4.5 Interaction with other medicines and other forms of interaction**

**CYP3A4 Interactions**

Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other medicines metabolised by CYP3A4.
Potent inhibitors of CYP3A4 (e.g. Itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, nefazodone) increase the risk of myopathy by reducing the elimination of simvastatin (see below).

Concomitant use with medicines labelled as having a potent inhibitory effect on CYP3A4 (e.g. Itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, or nefazodone) is contraindicated (see sections 4.3, 4.4).

Concomitant use with gemfibrozil, cyclosporine or danazol is contraindicated: (see sections 4.3 and 4.4).

**Other medicine interactions**

Amiodarone: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone with higher doses of simvastatin (see section 4.4).

Calcium channel blockers: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of verapamil, diltiazem, or amlodipine (see sections 4.2 and 4.4).

Moderate inhibitors of CYP3A4: Patients taking other medicines labelled as having a moderate inhibitory effect on CYP3A4 concomitantly with SIMSTATIN, particularly higher SIMSTATIN doses, may have an increased risk of myopathy.

Fusidic Acid: Patients on fusidic acid treated concomitantly with simvastatin may have an increased risk of myopathy (see sections 4.4 and 5.2).

Colchicine: There have been reports of myopathy and rhabdomyolysis with the concomitant administration of colchicine and simvastatin in patients with renal insufficiency.

Niacin (nicotinic acid) (≥1 g/day): Cases of myopathy/rhabdomyolysis have been observed with simvastatin co-administered with lipid modifying doses (≥1 g/day) of niacin (see section 4.4).

**Other interactions**

Grapefruit juice contains one or more components that inhibit CYP3A4 and can increase the plasma levels of medicines metabolised by CYP3A4. The effect of typical consumption (one 250-ml glass daily) is minimal (13% increase in active plasma HMG-CoA reductase inhibitory activity as measured by the area under the concentration-time curve) and of no clinical relevance. However, very large quantities (over 1 litre daily) significantly increase the plasma levels of HMG-CoA reductase inhibitory activity during simvastatin therapy and should be avoided (see section 4.4).

**Coumarin Derivatives**

In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalised Ratio (INR),
increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively. In patients taking coumarin anticoagulants, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of simvastatin is changed or discontinued, the same procedure should be repeated. Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.

Medicine interaction studies were performed with the following compounds.

**Propranolol**

In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of simvastatin and propranolol.

**Digoxin**

Concomitant administration of simvastatin and digoxin in normal volunteers resulted in a slight elevation (less than 0.3ng/ml) in medicine concentrations (as measured by a digoxin radioimmunoassay) in plasma compared to concomitant administration of placebo and digoxin.

**Other Concomitant Therapy**

In clinical studies, simvastatin was used concomitantly with angiotensin converting enzyme (ACE) inhibitors, beta blockers, diuretics and nonsteroidal anti-inflammatory medicines (NSAIDs) without evidence of clinically significant adverse interactions.

### 4.6 Fertility, pregnancy and lactation

Category D.

Safety in pregnant women has not been established. No controlled clinical trials with simvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. However, in an analysis of approximately 200 prospectively followed pregnancies exposed during the first trimester to SimStatin or another closely related HMG-CoA reductase inhibitor, the incidence of congenital anomalies was comparable to that seen in the general population. This number of pregnancies was statistically sufficient to exclude a 2.5-fold or greater increase in congenital anomalies over the background incidence.

Although there is no evidence that the incidence of congenital anomalies in offspring of patients taking SimStatin or another closely related HMG-CoA reductase inhibitor differs from that observed in the general population, maternal treatment with SimStatin may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atherosclerosis is
a chronic process, and ordinarily discontinuation of lipid-lowering medicines during pregnancy
should have little impact on the long-term risk associated with primary hypercholesterolemia.
For these reasons, SimStatin should not be used in women who are pregnant, trying to become
pregnant or suspect they are pregnant. Treatment with SimStatin should be suspended for the
duration of pregnancy or until it has been determined that the woman is not pregnant.

**Nursing Mothers**

It is not known whether simvastatin or its metabolites are excreted in human milk. Because
many medicines are excreted in human milk and because of the potential for serious adverse
reactions, women taking SimStatin should not breast feed their infants.

**4.7 Effects on ability to drive and use machines**

SimStatin is presumed to be safe and unlikely to produce an effect on the ability to drive or use
machinery.

**4.8 Undesirable effects**

SimStatin is generally well-tolerated; for the most part adverse effects have been mild and
transient in nature. Less than 2 percent of patients were discontinued from controlled clinical
studies due to adverse effects attributable to simvastatin.

In the pre-marketing controlled clinical studies, adverse effects occurring with a frequency of
1 percent or more and considered by the investigator as possibly, probably or definitely
medicine-related were: abdominal pain, constipation and flatulence. Other adverse effects
occurring in 0.5 - 0.9 percent of patients were asthenia, headache, acid regurgitation,
diarrhoea, dyspepsia and insomnia.

Myopathy has been reported rarely.

In the Heart Protection Study involving 20, 536 patients treated with 40mg/day of simvastatin
\(n = 10,269\) or placebo \(n = 10,267\), the safety profiles were comparable between patients
treated with simvastatin and patients treated with placebo over the mean 5 years of the study.
In this mega-trial, only serious adverse effects and discontinuations due to any adverse effects
were recorded. Discontinuation rates due to adverse effects were comparable (4.8% in
patients treated with simvastatin compared with 5.1% in patients treated with placebo). The
incidence of myopathy was < 0.1% in patients treated with simvastatin. Elevated transaminases
(>3X ULN confirmed by repeat test) occurred in 0.21% \(n = 21\) of patients treated with
simvastatin compared with 0.09% \(n = 9\) of patients treated with placebo.

In 4S, involving 4444 patients treated with 20-40 mg/day of simvastatin \(n=2221\) or placebo
\(n=2223\), the safety and tolerability profiles were comparable between treatment groups over
the median 5.4 years of the study.
The following additional adverse effects were reported either in uncontrolled clinical studies or in marketed use: nausea, diarrhoea, rash, dyspepsia, pruritis, alopecia, dizziness, muscle cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, cognitive impairment, depression, vomiting, anaemia, gynaecomastia, sleep disturbances including insomnia and nightmares and erectile dysfunction.

Rarely rhabdomyolysis and hepatitis/jaundice, and very rarely fatal and non-fatal hepatic failure have occurred. An apparent hypersensitivity syndrome has been reported rarely which has included some of the following features: anaphylaxis, angioedema, lupus-like syndrome, polymyalgia rheumatica, dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, ESR increased, arthritis, arthralgia, urticaria, photosensitivity, fever, flushing, dyspnoea and malaise.

There have been rare post marketing reports of cognitive impairment (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. There cognitive issues have been reported for all statins. The reports are generally non-serious, and reversible upon discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).

The following adverse events have been reported with some statins:
- Sleep disturbances, including insomnia and nightmares
- Memory loss
- Sexual dysfunction
- Depression
- Exceptional cases of interstitial lung disease, especially with long term therapy

There have been very rare reports of immune-mediated necrotising myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterised by proximal muscle weakness and elevated serum creatine kinase, which persists despite discontinuation of statin treatment; muscle biopsy showing necrotising myopathy without significant inflammation; improvement with immunosuppressive agents (see section 4.4).

**Laboratory Test Findings**

Marked and persistent increases of serum transaminases have been reported infrequently. Elevated alkaline phosphatase and γ-glutamyl transpeptidase have been reported. Liver function test abnormalities have generally been mild and transient. Increases in CK levels, derived from skeletal muscle, have been reported (see section 4.4).

**Paediatric Patients (Ages 10-17 years)**

In a study involving paediatric patients 10-17 years of age with heterozygous familial hypercholesterolemia (n = 175), the safety and tolerability profile of the group treated with simvastatin was generally similar to that of the group treated with placebo.
Adverse Effects - Causal Relationship Unknown

The following adverse effects have been reported; however, a causal relationship to therapy with simvastatin has not been established: depression, erythema multiforme including Stevens-Johnson syndrome, leukopaenia and purpura.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions https://nzphvc.otago.ac.nz/reporting/

4.9 Overdose

A few cases of overdosage have been reported; the maximum dose taken was 3.6g. All patients recovered without sequelae. General measures should be adopted.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Simvastatin is a lipid-lowering agent derived synthetically from a fermentation product of Aspergillus terreus.

After oral ingestion, Simvastatin, an inactive lactone, is hydrolysed to the corresponding β-hydroxyacid form. This is a principal metabolite and an inhibitor of HMG-CoA reductase, the enzyme that catalyses an early and rate-limiting step in the biosynthesis of cholesterol. Clinical studies show simvastatin to be highly effective in reducing total-C, LDL-C, TG, and very-low-density lipoprotein cholesterol (VLDL-C) concentrations, and increasing HDL-C in heterozygous familial and non-familial forms of hypercholesterolemia, and in mixed hyperlipidemia when elevated cholesterol was cause for concern and diet alone has been insufficient. Marked responses are seen within 2 weeks, and maximum therapeutic responses occur within 4-6 weeks. The response is maintained during continuation of therapy. When therapy with simvasatin is stopped, cholesterol and lipids return to pretreatment levels.

The active form of simvastatin is a specific inhibitor of HMG-CoA reductase, the enzyme which catalyses the conversion of HMG-CoA to mevalonate. Because the conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway of cholesterol, therapy with SimStatin would not be expected to cause an accumulation of potentially toxic sterols. In addition, HMG-CoA is also metabolised readily back to acetyl-CoA, which participates in many biosynthetic processes in the body.

In animal studies, after oral dosing, simvastatin had high selectivity for the liver, where it achieved substantially higher concentrations than in non-target tissues. Simvastatin undergoes extensive first-pass extraction in the liver, the primary site of action, with subsequent excretion.
of medicine in the bile. Systemic exposure of the active form of simvastatin in humans has been found to be less than 5% of the oral dose. Of this, 95% is bound to human plasma proteins.

SimStatin raises HDL-C and therefore lowers the LDL-C/HDL-C and total-C/HDL-C ratios.

5.2 Pharmacokinetic properties

Simvastatin is an inactive lactone which is readily hydrolysed in vivo to the corresponding β-hydroxyacid, L-654,969, a potent inhibitor of HMG-CoA reductase. Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the β-hydroxyacid metabolites (active inhibitors) and, following base hydrolysisis, active plus latent inhibitors (total inhibitors). Both are measured in plasma following administration of simvastatin.

In a disposition study with 14C-labelled simvastatin, 100mg (20 uCi) of medicine was administered as capsules (5 x 20mg), and blood, urine, and faeces collected. Thirteen percent of the radioactivity was recovered in the urine and 60 percent in faeces. The latter represents absorbed medicine equivalents excreted in bile as well as unabsorbed medicine. Less than 0.5 percent of the dose was recovered in urine as HMG-CoA reductase inhibitors. In plasma, the inhibitors account for 14 percent and 28 percent (active and total inhibitors) of the AUC of total radioactivity, indicating that the majority of chemical species present were inactive or weak inhibitors.

Both simvastatin and L-654,969 are bound to human plasma proteins (95%). The major metabolites of simvastatin present in human plasma are L-654,969 and four additional active metabolites. The availability of L-654,969 to the systemic circulation following an oral dose of simvastatin was estimated using an IV reference dose of L-654,969; the value was found to be less than 5 percent of the dose. By analogy to the dog model, simvastatin is well absorbed and undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of medicine equivalents in the bile. Consequently, availability of active medicine to the general circulation is low.

In dose-proportionality studies utilising doses of simvastatin of 5, 10, 20, 60, 90 and 120mg there was no substantial deviation from linearity of AUC of inhibitors in the general circulation with an increase in dose. Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before a test meal.

The pharmacokinetics of single and multiple doses of simvastatin showed that no accumulation of medicine occurred after multiple dosing. In all of the above pharmacokinetic studies, the maximum plasma concentration of inhibitors occurred 1.3 to 2.4 hours post dose.

In a study of patients with severe renal insufficiency (creatinine clearance <30ml/min), the plasma concentrations of total inhibitors after a single dose of a related HMG-CoA reductase inhibitor were approximately two-fold higher than those in healthy volunteers.

In a study of 12 healthy volunteers, simvastatin at the maximal 80-mg dose had no effect on the metabolism of the probe CYP3A4 substrates midazolam and erythromycin. This indicates
that simvastatin is not an inhibitor of CYP3A4, and therefore, is not expected to affect the plasma levels of other medicines metabolised by CYP3A4.

Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of HMG-CoA reductase inhibitors. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4.

The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Potent inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy (see sections 4.4 and 4.5).

No pharmacokinetic studies have been conducted to date in elderly patients or in patients with renal or hepatic dysfunction.

5.3 Preclinical safety data

Reproductive and Developmental Toxicity

At maximally tolerated doses in both the rat and the rabbit, simvastatin produced no foetal malformations and had no effects on fertility, reproductive function or neonatal development. However, in rats, an oral dose of 60 mg/kg/day of the hydroxy acid, pharmacologically active metabolite of simvastatin resulted in decreased maternal body weight and an increased incidence of foetal resorptions and skeletal malformations compared with controls. Subsequent studies conducted at dosages of up to 60 mg/kg/day with this metabolite showed that these resorptions and skeletal malformations were consequences of maternal toxicity (forestomach lesions associated with maternal weight loss) specific to rodents and are highly unlikely to be due to a direct effect on the developing foetus. Although no studies have been conducted with simvastatin, maternal treatment of pregnant rats with a closely related HMG-CoA reductase inhibitor at dosages of 80 and 400 mg/kg/day (10- and 52-fold the maximum recommended therapeutic dose based on mg/m² body surface area) has been shown to reduce the foetal plasma levels of mevalonate.

Genetic Toxicology and Carcinogenicity

An extensive battery of in vitro and in vivo genetic toxicity tests have been conducted on both simvastatin and its corresponding open acid L-654,969. These include assays for microbial mutagenesis, mammalian cell mutagenesis, single stranded DNA breakage and tests for chromosome aberrations. The results of these studies provided no evidence of an interaction between simvastatin or L-654,969 with genetic material at the highest soluble noncytotoxic concentrations tested in in vitro assay systems or at maximally tolerated doses tested in vivo.

Initial carcinogenicity studies conducted in rats and mice with simvastatin employed doses ranging from 1mg/kg/day to 25mg/kg/day. No evidence of a treatment-related incidence of tumour types was found in mice in any tissue. A statistically significant (p ≤ 0.05) increase in the incidence of thyroid follicular cell adenomas was observed in female rats receiving 25mg/kg of simvastatin per day (more than an order of magnitude greater than the maximum human dose). This benign tumour type was limited to female rats; no similar changes were seen in male rats or in female rats at lower dosages (up to 5mg/kg/day). These tumours are a
secondary effect reflective of a simvastatin-mediated enhancement of thyroid hormone clearance in the female rat. No other statistically significant increased evidence of tumour types was identified in any tissues in rats receiving simvastatin.

Data from both of these studies indicated that squamous epithelial hyperplasia of the forestomach occurred at all dosage levels. These gastric changes are confined to an anatomical structure which is not found in humans. Moreover, identical cells found in other locations (e.g. oesophagus and anorectal junction of the rat, mouse and dog) are unaffected.

Results of an additional 73-week carcinogenicity study in mice receiving simvastatin doses up to 400 mg/kg/day (more than 2 orders of magnitude greater than the maximum human dose) exhibited increased incidences of hepatocellular adenomas and carcinomas, pulmonary adenomas and harderior gland adenomas. A no-effect dose of 25 mg/kg/day (again, more than an order of magnitude greater than the maximum human dose) was established in this study and from the results of the initial 92-week carcinogenicity study in mice.

Results of an additional 106-week carcinogenicity study in rats receiving simvastatin doses ranging from 50 mg/kg/day to 100 mg/kg/day (more than an order of magnitude greater than the maximum human dose) exhibited a treatment-related increase in the incidence of hepatocellular neoplasms. The no-effect dose remains at 25 mg/kg/day (more than an order of magnitude greater than the maximum human dose) as established in the initial carcinogenicity study. An increase in the incidence of thyroid hyperplastic lesions was also observed; however, this is consistent with the previous finding that this is a species-specific response and has no implications for man.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
SimStatin 5mg, 10mg, 20mg, 40mg and 80mg contain the following excipients:

- Butylated hydroxyanisole
- Hyprolose
- Hypromellose
- Lactose
- Magnesium stearate
- Microcrystalline cellulose
- Pregelatinised maize starch
- Purified talc
- Titanium dioxide

In addition, the 5mg tablets contain Iron oxide yellow

6.2 Incompatibilities

Not applicable.
6.3 Shelf life

36 months.

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

SimStatin 5mg, 10mg, 20mg, 40mg and 80mg tablets are available as blister packs of 30 tablets.

6.6 Special precautions for disposal

No special requirements.

7 MEDICINE SCHEDULE

Prescription Medicine

8 SPONSOR

AFT Pharmaceuticals Ltd
PO Box 33.203
Takapuna
Auckland
Email:customer.service@aftpharm.com

9 DATE OF FIRST APPROVAL

SimStatin 5 mg, 10 mg, 20 mg and 40 mg tablets: 18 January 2007
SimStatin 80 mg tablets: 01 February 2007

10 DATE OF REVISION OF THE TEXT

20 August 2018
## SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Date</th>
<th>Section(s) Changed</th>
<th>Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14 August 2018</td>
<td>All</td>
<td>Reformat consistent with new Medsafe Data Sheet Template.</td>
</tr>
<tr>
<td>14 August 2018</td>
<td>4.8</td>
<td>Update to include “anaphylaxis” in Undesirable effects section as per Medsafe’s request dated 04 July 2018.</td>
</tr>
</tbody>
</table>